Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20485512 | 0.87 | ALDH1A1 (0.58) | ALDH1A1LMNACYP1A2CYP2C19NPC1 | |
| Hydrogen Peroxide SCHEMBL29219018 | 0.81 | LMNA (0.56) | ALDH1A1LMNACYP2D6HSD17B10SMN1; SMN2 | |
| SCHEMBL266279 | 0.81 | LMNA (0.56) | ALDH1A1LMNACYP2D6HSD17B10SMN1; SMN2 | |
| SCHEMBL23069546 | 0.80 | L3MBTL1 (0.60) | ALDH1A1LMNACYP1A2CYP2C19NPC1 | |
| SCHEMBL10579985 | 0.80 | HSD17B3 (0.58) | ALDH1A1LMNACYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8995839 | 0.80 | TDP1 (0.52) | ALDH1A1LMNACYP1A2NPC1CYP3A4 | |
| SCHEMBL28255372 | 0.80 | LMNA (0.55) | ALDH1A1LMNACYP2D6HSD17B10SMN1; SMN2 | |
| SCHEMBL27844964 | 0.79 | CYP1A2 (0.49) | ALDH1A1LMNACYP1A2CYP2C19NPC1 | |
| SCHEMBL4688387 | 0.79 | HTR7 (0.51) | ALDH1A1CYP1A2NPC1SMN1; SMN2KMT2A | |
| SCHEMBL8591084 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNACYP1A2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479803-B2 | Antimalarial compounds | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220204452-A1 | ANTIMALARIAL COMPOUNDS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2022-06-30 | — | — | US | disclosed |
| WO-2020206252-A1 | ANTIMALARIAL COMPOUNDS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2003062227-A1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| US-5026711-A | Prevention and treatment of cardiovascular disorders and infections states; anxiolytic and anti-allergic agents | SANOFI (FR) | 1991-06-25 | — | — | US | disclosed |
| US-4127583-A | Preparation of 3-(pyridinyl)-2-cyclohexene-1-ones | STERLING DRUG INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4026900-A | 3-(Pyridinyl)-2-cyclohexen-1-ones | STERLING DRUG INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-3947462-A | 2,4,7-substituted 5-hydroxy benzopyrans and esters | ABBOTT LABORATORIES (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ALDH1A1 3690/4885LMNA 3296/4885CYP1A2 1810/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | ALDH1A1 3690/4885LMNA 3296/4885CYP1A2 1810/4885 |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | ALDH1A1 1737/4885LMNA 1616/4885CYP1A2 3844/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | ALDH1A1 2590/4885LMNA 3522/4885CYP1A2 1660/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ALDH1A1 3690/4885LMNA 3296/4885CYP1A2 1810/4885 |
| US-12479803-B2 | Antimalarial compounds | H1-3, FPR3, NHERF1 | ALDH1A1 3012/4885LMNA 632/4885CYP1A2 255/4885 |
| US-20220204452-A1 | ANTIMALARIAL COMPOUNDS | H1-3, FPR3, NHERF1 | ALDH1A1 3012/4885LMNA 632/4885CYP1A2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.